“Ninety percent of girls are fully vaccinated with the HPV vaccine by age 15, 70 percent of women are screened with a ...

CEO Frank Bedu-Addo highlighted the initiation of the VERSATILE 003 Phase 3 clinical trial of Versamune HPV plus pembrolizumab for first-line recurrence and/or metastatic HPV16-positive head and neck ...

Nearly all newborns who contract human papillomavirus in the perinatal stage will eliminate the virus in the first six months ...

Greetings and welcome to the PDS Biotech first quarter in 2025 earnings conference call. (operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce ...

Researchers in Uruguay say wastewater monitoring of the human papillomavirus (HPV) can give important information about its presence in the population.

The Food and Drug Administration just approved an at home test that could be an optional alternative to a yearly pap smear.

PDS Biotechnology Corp (PDSB) reports reduced net loss and strategic clinical trial progress, despite ongoing financial hurdles.

The Teal Wand, an at-home HPV testing device that could replace a Pap smear, could broaden access to cervical cancer screening.

The U.S. Food and Drug Administration approved the Teal Wand as the first alternative to in-office Pap smears, which many ...

PDS Biotechnology Corporation (NASDAQ: PDSB) Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation ...

Davao City's CHO reports a decrease in cervical cancer deaths but expresses concern over declining screening rates. Dr. Sharlene Tan emphasizes HPV vaccination for young girls and accessible VIA ...